{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:21:25Z","timestamp":1787818885459,"version":"build-2784847793"},"reference-count":31,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Clinical guidelines remain the foundation of evidence-based oncology, translating population-derived evidence into treatment recommendations for defined patient groups. However, patients with rare cancers, complex tumor biology, or treatment-refractory disease may reach a point at which applicable evidence is limited, or guideline-recommended treatment options have been exhausted. We propose Personalized Oncology as a complementary framework for treatment selection in these situations. Rather than asking only which treatments benefited similar patients, Personalized Oncology asks which available treatment is expected to provide the most favorable benefit\u2013risk profile for the individual patient. It does so by integrating population-derived medical evidence with patient-specific biological evidence generated from the individual cancer. Importantly, exhaustion of guideline-recommended treatments does not necessarily mean exhaustion of biologically supported treatment opportunities. The supporting evidence, rationale, alternatives, limitations, and uncertainty are documented to enable transparent clinical decision-making. Neither population-derived evidence nor patient-specific biological evidence determines in advance whether an individual patient will benefit. Treatment response must therefore be systematically monitored and incorporated into subsequent decisions. Personalized Oncology standardizes this process while preserving individualized clinical judgment. Systematic capture of each patient\u2019s biology, treatment, and outcome can create a continuous learning framework in which experience from individual patients informs future cancer care.<\/jats:p>","DOI":"10.3390\/cancers18172778","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:02:27Z","timestamp":1787817747000},"page":"2778","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized Oncology: Organizing Cancer Treatment Around Patient Biology"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3349-4495","authenticated-orcid":false,"given":"Julianna","family":"Lisziewicz","sequence":"first","affiliation":[{"name":"VERDI Solutions GmbH, 1010 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Wueseke","sequence":"additional","affiliation":[{"name":"ImmuLogics GmbH, 48155 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Lori","sequence":"additional","affiliation":[{"name":"VERDI Solutions GmbH, 1010 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2013.49.4799","article-title":"Precision oncology: An overview","volume":"31","author":"Garraway","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: Evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_4","unstructured":"Institute of Medicine (2013). Best Care at Lower Cost: The Path to Continuously Learning Health Care in America, The National Academies Press."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jbi.2016.09.018","article-title":"The learning healthcare system: Where are we now? A systematic review","volume":"64","author":"Budrionis","year":"2016","journal-title":"J. Biomed. Inform."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: The I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na\u00efve study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41571-023-00824-4","article-title":"Molecular tumour boards\u2014Current and future considerations for precision oncology","volume":"20","author":"Tsimberidou","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/PO.20.00495","article-title":"Clinical outcomes of molecular tumor boards: A systematic review","volume":"5","author":"Larson","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41698-025-00865-1","article-title":"Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps","volume":"9","author":"Gladstone","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"110465","DOI":"10.1016\/j.isci.2024.110465","article-title":"Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy","volume":"27","author":"Louie","year":"2024","journal-title":"iScience"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: What it is and what it isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","article-title":"The next generation of evidence-based medicine","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s13167-021-00254-1","article-title":"Personalization of medical treatments in oncology: Time for rethinking the disease concept to improve individual outcomes","volume":"12","author":"Bizzarri","year":"2021","journal-title":"EPMA J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Van de Vliet, P., Sprenger, T., Kampers, L.F.C., Makalowski, J., Schirrmacher, V., St\u00fccker, W., and Van Gool, S.W. (2023). The application of evidence-based medicine in individualized medicine. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071793"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: The WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1003221","DOI":"10.37349\/ei.2025.1003221","article-title":"Personalized peptide vaccines induce predicted T cell responses against signet ring cell carcinoma\u2014A case report","volume":"5","author":"Lisziewicz","year":"2025","journal-title":"Explor. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1038\/s41467-024-51315-8","article-title":"A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine","volume":"15","author":"Latzer","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e00747","DOI":"10.7554\/eLife.00747","article-title":"Evolutionary dynamics of cancer in response to targeted combination therapy","volume":"2","author":"Bozic","year":"2013","journal-title":"eLife"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41568-026-00922-2","article-title":"Advancing AI for multi-omics and clinical data integration in basic and translational cancer research","volume":"26","author":"Liu","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrg.2017.113","article-title":"Cloud computing for genomic data analysis and collaboration","volume":"19","author":"Langmead","year":"2018","journal-title":"Nat. Rev. Genet."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:12:41Z","timestamp":1787818361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":31,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172778"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172778","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}